Abstract
Viviana Perez, APRN, FNP-C, of Moffitt Cancer Center, considers real-world outcomes presented at the 2024 ASH Annual Meeting of momelotinib, a JAK1/JAK2/ACVR1 inhibitor that has shown promise in treating myelofibrosis in patients with anemia.
Visit https://jadpro.com/videos/meeting-highlights/ for short videos about these important abstracts.
